about
Relationship between serum soluble vascular adhesion protein-1 level and gastric cancer prognosisHigh-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestosIs there any significance of lung cancer histology to compare the diagnostic accuracies of (18)F-FDG-PET/CT and (99m)Tc-MDP BS for the detection of bone metastases in advanced NSCLC?Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology.Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients.Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?Complementary and alternative medicine usage in cancer patients in southeast of TurkeyEpidemiological and clinical characteristics of malignant melanoma in Southeast Anatolia in Turkey.Increased bone mineral density in patients with non-alcoholic steatohepatitis.Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience.Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study.Prevalence and predictive factors for development of splenic artery aneurysms in cirrhosis.Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology).Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?Erratum to: High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring asbestos.A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).Childhood, adolescents, and young adults (≤25 y) colorectal cancer: study of Anatolian Society of Medical Oncology.Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey.Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.Testicular Mass: An Initial Sign of Squamous Cell Carcinoma of the Lung.Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group.Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with advanced non-small cell lung cancer: single center experience.Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.The value of micro-ELISA test in the diagnosis of Fasciola hepatica infection.
P50
Q28241449-6CC88DA9-9958-43C9-971F-8090488FB8F2Q28388266-BB413BB8-B664-4AD3-976C-2D32DA417F10Q33799242-C976E3C8-BD9D-4051-BC39-AC7E27D066E5Q34226740-CC441CB7-900D-4D7A-A180-4F27473FF8C1Q34656707-D89408B8-CE89-4DE6-82FA-7BBEBB168745Q36105556-225C2B75-6E47-4169-B349-31ACF9D89D29Q36942640-B9430060-EC24-4306-B498-04B4F1D5DFC0Q37102409-2F63E0EF-1D24-4A34-B2CD-366C9DFDF666Q37192293-9BD91EB4-DDFD-4D34-A697-2F4B0794CDBFQ37358283-6C81F74E-A36F-4D21-9A8B-C7B0E0D62D58Q37677684-447D29E6-7635-4463-960F-89BE01A9C1AEQ38064719-2E9BD3AE-EF47-4BAA-91A8-5F29DF13B16DQ38668195-A4C7D12A-725C-4BD1-8372-2328081B1E37Q38692427-858AF912-B7EC-46AB-8B5E-63124B0847DDQ38858911-33CEC47C-8B0F-4362-9D63-E57A5B1F5DF5Q41212534-A2368C26-2E7B-48DD-AACD-2B4E202F25B6Q41498165-B955855B-6910-40AE-A3D1-781BDF0DFCE3Q41757239-B6DE4849-6646-4C20-B6E0-A3B230F3134CQ42606484-DACCA85C-56A4-42CE-97AE-0A55DDA9AF6CQ42873402-42483E25-5617-4A6C-9751-AADB5F98E15DQ43466291-20C2E02B-AF7E-4871-BABB-C9C1BA6B7E51Q43590761-7266B9A6-6186-42CF-85F1-863BF2EEED91Q43946441-EC93279A-C9B8-4E17-8C9B-2CAE56EC1CCDQ44625585-FC71F376-C8D2-49E5-A70B-4966C9D053DEQ45783443-188DB2E7-CF6A-4991-936F-C76BCB34CC78Q45913017-7A9FF0E1-8D8A-4333-9935-18FBAC6580F6Q46893138-25E73E9D-3815-449F-A7D2-FB291CC97156Q46972350-5DC1A828-D4F5-42DD-A3B7-D407BE4BA647Q47141778-5CD84D32-F107-48BB-94B3-63A1ABF3E394Q47154370-A2E9A468-F854-4066-B3FC-EC2601930503Q47314699-01F1941D-A61B-496A-8CE7-39C2169EAFB6Q47590609-24A889F3-3FAE-4B2B-9944-B84FBE2A267CQ47840383-FE7FDA0B-3DD7-44DE-9A94-BE35E23837A5Q48831498-CBED9714-B748-4232-BE9D-AA27C48AC0CAQ50144042-97F84DAC-B4F6-49F1-87C7-B63F3A3329D3Q50501388-B7BC3990-4FCD-41BD-9A2F-94E1FF650BF6Q50777668-45C6F1EC-A2AC-47D3-9EC1-A4A6F93474E0Q50878426-336CFB6C-1088-44BA-BE93-30AD1378BA8BQ50927789-E6E1D9C0-CB86-4E0E-8045-DF1E0F879095Q51040509-2BB2C2CD-0DB7-4499-BBBC-BA08C4968083
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Muhammet Ali Kaplan
@en
Muhammet Ali Kaplan
@nl
type
label
Muhammet Ali Kaplan
@en
Muhammet Ali Kaplan
@nl
altLabel
Kaplan MA
@en
prefLabel
Muhammet Ali Kaplan
@en
Muhammet Ali Kaplan
@nl
P108
P31
P496
0000-0003-0882-0524